Skip to content

Erythropoeitin to facilitate stroke recovery

Erythropoeitin to facilitate stroke recovery: a randomised trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN50896492
Enrollment
90
Registered
2012-11-27
Start date
2012-11-01
Completion date
Unknown
Last updated
2017-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke Circulatory System Stroke, not specified as haemorrhage or infarction

Interventions

The research will be undertaken in three groups of 30 stroke patients each who are within 48 hours of stroke onset, have not been thrombolysed and have no contraindications to EPO treatment. All group

Sponsors

King's College Hospital NHS Foundation Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Supratentorial ischaemic stroke, confirmed on imaging 2. Recruited within 48 hours of stroke onset. Time of onset is when symptoms began; for stroke that occurred during sleep, time of onset is when patient was last seen or was selfreported to be normal 3. NIHSS score 624 with NIHSS 1A (level of consciousness) score <2 at the time of enrolment 4. Reasonable expectation of availability to receive the full course of therapy, and to be available for subsequent follow-up visits 5. Reasonable expectation that patient will receive standard poststroke physical, occupational and speech therapy as indicated

Exclusion criteria

Exclusion criteria: 1. Prestroke modified Rankin Score (mRS) >2 2. Thrombolytic treatment with tPA following the index stroke 3. Patients presenting with hemorrhagic and/or brain stem stroke 4. Women who may be pregnant or breastfeeding 5. Serum hemoglobin > 16 g/dL (males) or > 14 g/dL (females), or platelet count > 400,000/mm3 6. Advanced liver, kidney, cardiac or pulmonary disease (serum bilirubin > 1.5 x upper limit of normal (ULN), Alkaline phosphatase > 2.5 x ULN, GGT>2.5xULN 7. History of clotting disorders 8. Expected survival 220 mm Hg systolic or 120 mm Hg diastolic despite antihypertensive therapy) 13. Preexisting and active major psychiatric or other chronic neurological disease 14. Currently participating in another investigational study

Design outcomes

Primary

MeasureTime frame
Change in Fugl-Meyer scale score from baseline

Secondary

MeasureTime frame
No secondary outcome measures

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026